Dr. O'Donnell on Ongoing Immunotherapy Trials in Bladder Cancer

Peter O'Donnell, MD
Published: Wednesday, Nov 07, 2018



Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses ongoing immunotherapy trials in bladder cancer.

Physicians are eagerly anticipating trials of dual immunotherapy to see whether it will improve upon existing standards. There are 2 frontline trials where dual immunotherapy is being examined against chemotherapy as a standard backbone or single-agent immunotherapy, says O’Donnell. Moreover, triplets are being examined to see whether the addition of an immunotherapy agent can outperform a chemotherapy doublet. That could change the frontline standard, notes O’Donnell. Those combinations are on the near horizon, he says.

Aside from immunotherapy, there are many other targeted drugs that are in the pipeline. Even though immunotherapy has gained attention in the field, VEGF-targeted drugs are also being examined. An older trial looked at the combination of gemcitabine and cisplatin plus bevacizumab (Avastin), so there may be a role for a VEGF-targeted drug in bladder cancer.
SELECTED
LANGUAGE


Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses ongoing immunotherapy trials in bladder cancer.

Physicians are eagerly anticipating trials of dual immunotherapy to see whether it will improve upon existing standards. There are 2 frontline trials where dual immunotherapy is being examined against chemotherapy as a standard backbone or single-agent immunotherapy, says O’Donnell. Moreover, triplets are being examined to see whether the addition of an immunotherapy agent can outperform a chemotherapy doublet. That could change the frontline standard, notes O’Donnell. Those combinations are on the near horizon, he says.

Aside from immunotherapy, there are many other targeted drugs that are in the pipeline. Even though immunotherapy has gained attention in the field, VEGF-targeted drugs are also being examined. An older trial looked at the combination of gemcitabine and cisplatin plus bevacizumab (Avastin), so there may be a role for a VEGF-targeted drug in bladder cancer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x